Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel.
In this webinar, you will hear how the Tempus platform can support development of new therapies by combining real-world data, next-generation sequencing, and artificial-intelligence to advance precision oncology. Our regulatory and scientific experts will provide an overview of the pathways for diagnostics and share best practices for biopharma and biotech sponsors to consider in clinical trial design and the development of companion diagnostics.
Listen to industry leaders discuss longitudinal endpoints for disease progression, the evolving role of liquid biopsy within drug development, and the value of methylation in combination with liquid biopsy.
Watch replay
The traditional model of activating clinical trials is widely acknowledged as inefficient. The process of establishing a clinical site, negotiating partnerships between sites and sponsors, then attempting to recruit eligible patients in nearby areas can take many months, and it becomes a burden to trial site staff, sponsors, and patients.
Read more
Mike Yasiejko, General Manager and Executive Vice President at Tempus, recently spoke with Andrew Mazar, PhD, Chief Operating Officer at Actuate Therapeutics, about the ways Tempus’ liquid biopsy (xF+) and methylation assays have been valuable to Actuate’s work and how the company has benefitted from the partnership
Read more
